Please login to the form below

Not currently logged in
Email:
Password:

David Holliday joins Octapharma USA as VP commercial development

Moves from Baxter Bioscience to take up senior sales and marketing role in the US

David Holliday - Octapharma USAOctapharma USA has appointed Baxter Bioscience's former VP of global marketing operations and haemophilia as its new VP of commercial development.

David Holliday will lead all US product marketing, sales and commercial activities at Octapharma, along with co-ordinating its global portfolio development initiatives.

The company is the US affiliate of Swiss-headquartered Octapharma AG, which develops and manufactures human protein products.

Holliday spent eight years at Baxter, gaining US and international experience in management, sales, marketing and business development, and was responsible for several successful product launches.

Prior to his time at Baxter, he held leadership positions at both Novartis and Ciba-Geigy Pharmaceuticals.

“We are very excited to have David Holliday, a true global leader in our industry, join our senior management team,” said Octapharma's USA president, Flemming Nielsen.

“He joins Octapharma USA at an extremely important time for our company as our product portfolio in the US will be increasing significantly in the next year and we expect David will be integral to our growth.”

26th January 2012

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...